Connacht Asset Management LP Mirati Therapeutics, Inc. Transaction History

Connacht Asset Management LP

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 14, 2023	BUY	$36.13 - $49.49 $29,048 - $39,789	804 Added 13.41%	6,798 $245,000
Q1 2023 May 15, 2023	SELL	$36.54 - $54.26 $41,692 - $61,910	-1,141 Reduced 15.99%	5,994 $222,000
Q4 2022 Feb 14, 2023	BUY	$41.27 - $98.62 $163,429 - $390,535	3,960 Added 124.72%	7,135 $323,000
Q3 2022 Nov 14, 2022	SELL	$59.5 - $86.7 $12,614 - $18,380	-212 Reduced 6.26%	3,175 $222,000
Q2 2022 Aug 15, 2022	BUY	$39.16 - $88.71 $2,702 - $6,120	69 Added 2.08%	3,387 $227,000
Q1 2022 May 16, 2022	SELL	$75.82 - $150.97 $237,923 - $473,743	-3,138 Reduced 48.61%	3,318 $273,000
Q4 2021 Feb 11, 2022	BUY	$132.01 - $190.29 $852,256 - $1.23 Million	6,456 New	6,456 $947,000

3.57M

36.6K

Ticker MRTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 55,609,800
Description
Mirati Therapeutics, Inc., a clinical-stage oncology company, develops product candidates to address the genetic and immunological promoters of cancer in the United States. The company develops MRTX849, a KRAS G12C inhibitor, which is in Phase 1/2 clinical trial for treating non-small cell lung (NSCL), colorectal, pancreatic, and other cancers; ...

Get notified when there are updates to the investment portfolio of Connacht Asset Management LP, based on Form 13F filings with the SEC.

Stay updated on Connacht Asset Management LP with notifications on news.